This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Response Genetics Announces Presentation Of Lung Cancer And Esophageal Cancer Study Results At 2011 American Society Of Clinical Oncology Annual Meeting

General Poster Sections

Saturday June 4, 2:00 p.m. to 6:00 p.m. CT, Hall A

Abstract No. 7056: BRCA1 mRNA expression patterns in a large lung cancer cohort.

In lung cancer, low expression of the DNA repair gene ERCC1 is associated with platinum responsiveness. Expression of a second important DNA repair gene, BRCA1, was quantified in NSCLC tumor samples to determine potential regulatory relationships between the genes and to tumor histology and patient demographics. Of the 425 tumor specimens tested, no association was observed between either gene and patient age or gender. A significant association with histology, however, was identified – media BRCA1 gene expression was higher in squamous cell versus adenocarcinoma (2.39 versus 0.57; P<0.0001). A small but statistically significant positive correlation was also seen between BRCA1 and ERCC1 expression (P<0.001).

Monday June 6, 8:00 a.m. to noon CT., Hall A

Abstract No. 3053: Integrated research platform (iGXT) for enhancing drug development and personalizing cancer therapy: Pilot study results.

A unique approach was taken to test the feasibility of integrating data derived from multiple research models to optimize drug development and treatment strategies. Preclinical data from two mouse models – one possessing tumors with defined EGFR-related characteristics and a second hosting NSCLC patient-derived xenografts – were tested for molecular targets of interest. Information from these and other sources were used to validate the approach and to extrapolate back to individual patient information. Findings from this study may help advance understanding of intra-patient tumor differences to improve personalized cancer therapy.

About Response Genetics, Inc.

Response Genetics, Inc. (“RGI”) is focused on the development and sale of molecular diagnostic tests for cancer. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, the Company generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. RGI was founded in 1999, and its principal headquarters are located in Los Angeles, California. For more information, please visit

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the ability of the Company to expand its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric panels, the potential of using the results of this research to be included in cancer care guidelines, the usefulness of genetic information to tailor treatment to patients, the usefulness of gene profiling as a predictor of response to chemotherapy in lung, gastric and colorectal cancers, and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions.

These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs